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AbstrAct
Introduction: Patients hospitalised in intensive care units (ICU) are patients in severe health, who are at risk of serious 
hospital infections. Despite the development of medicine, developed procedures, management strategies, and high 
awareness of medical personnel, hospital infections are still a very big problem. One of the serious hospital infections 
is Clostridioides difficile, especially in ICU patients, which can even be fatal. The severity of the infection and its com-
plications, which hamper treatment and care, are a challenge for the entire therapeutic team. At the same time, this 
infection is a major epidemiological threat and increases the cost of treatment. That is why the diagnosis of infection, 
the application of the recommended treatment, as well as the correct prevention are so important. The basis for pre-
venting the spread of C. difficile infection is hand hygiene, the use of personal protective equipment, patient isolation, 
maintenance of disinfection, infected patient care, education of visitors, and monitoring and recording of infections.
Aim of the study: Discussing current data on treatment in the presence of C. difficile infection and describing prob-
lems faced by ICU medical personnel.
Conclusions: Following current recommendations for diagnosis and treatment and applying appropriate control 
procedures and methods contributes to preventing the spread of C. difficile infection in intensive care units.
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IntroductIon
Clostridioides difficile infection (CDI) develops in 
the large intestine, causing diarrhoea of varying se-
verity – from mild diarrhoea to pseudomembranous 
colitis and toxic megacolon with intestinal perfora-
tion. C. difficile infection may lead to complications 
like partial or total surgical removal of the large intes-
tine (colectomy), sepsis, and even death. Disruption 
of intestinal microflora after antimicrobial therapy 
has a decisive impact on the colonisation of the infec-
tion and the produced toxin. Transmission occurs in 
the faecal-oral route. Possible sources of infection in-
clude patients, hospital staff, visitors, medical equip-
ment, and the hospital environment [1-6]. This review 
article discusses the literature and current guidelines 
for limiting the spread of CDI in a  hospital setting. 
Most of the data were collected by analysing current 
Polish and foreign literature from PubMed (Medline).
rIsk factors
There are several risk factors for CDI:
• antibiotic therapy (long-term, multi-drug),
• patient age (> 65 years),
• long hospitalisations,
• hospitalisation in an intensive care units (ICU),
• immunodeficiency (acquired or congenital),




The main factor in the development of disease 
caused by C. difficile is antibiotic use. According to 
some authors, in 10-30% of cases of post-antibiotic 
use diarrhoea can be attributed to C. difficile [12, 13]. 
This applies especially to broad-spectrum antibiotics 
that are active against anaerobic bacteria and to which 
C. difficile is resistant. C. difficile diarrhoea is most com-
monly caused by the following antibiotics: fluroquino-
lones, second- and third-generation cephalosporins, 
clindamycin, ampicillin, amoxicillin, and broad-spec-
trum penicillins with inhibitors (except for ticarcillin 
with clavulanate and piperacillin with tazobactam) 
[1, 3, 4, 14, 15]. It is important to remember that any 
antibiotic can cause C. difficile-associated diarrhoea.
Many studies have also shown a significant effect 
of proton pump inhibitors on the increase of CDI in 
patients receiving high-risk antibiotics [8, 16, 17].
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Another significant problem in the treatment of 
patients is recurrent CDI, which may be caused by 
persistent resistant spores in the colon, an impaired 
immune response, or a  change in normal intestinal 
microflora [18-20]. The recurrence of the disease oc-
curs in 20-25% of patients [1].
Particular attention should be paid to critically ill 
patients who are at increased risk of developing di-
arrhoea. The disease makes treatment difficult, pro-
longs hospitalisation, but also exposes the patient to 
serious complications [21-23].
dIagnosIs
According to the European Centre for Disease Pre-
vention and Control (ECDC), for the diagnosis of CDI 
one of the following conditions should be met:
• loose stools or the presence abnormal dilation 
of the large intestine and positively confirmed 
through microbiological testing for the presence of 
toxins A and/or B, or the presence of a C. difficile 
strain producing the toxin(s) detected in the stool,
• the presence of pseudomembranous colitis deter-
mined in endoscopic examination,
• the presence of pseudomembranous colitis deter-
mined in histopathological examination [24].
Scales like the Bristol Stool Form Scale (BSF) or 
the Bliss Stool Chart may be useful in the assessment 
of stools; although, unfortunately, they are currently 
rarely used in ICUs [25, 26]. Apart from diarrhoea, 
symptoms of CDI may include the following: severe 
abdominal pain, fever, nausea, and vomiting. The 
above symptoms may lead to hypovolaemia, which is 
especially dangerous in ICU patients. 
Diagnostic testing for CDI should be ordered 
based on the above criteria. Routine testing in ICU 
patients or medical personnel is not recommended 
due to a high incidence of asymptomatic carriers. It 
is also not recommended to perform repeated tests 
during the same episode of diarrhoea, or cure tests. 
A positive CDI test result should be immediately re-
ported to the hospital infection control unit [27, 28].
The material used in testing for C. difficile is a liq-
uid, unformed stool sample. The sample, collected in 
a sterile test tube (approximately 3-5 ml), should be 
delivered to the appropriate laboratory within two 
hours of collection, at room temperature. If it is not 
possible to deliver the material in such a short time, 
samples should be stored in a refrigerator (also dur-
ing transport to the laboratory, which is not always 
obvious) at 4°C. The material can be stored for up 
to 72 hours in such a temperature, and if necessary, 
the sample can be frozen to –80°C. It is important to 
remember that storing the material in a refrigerator 
reduces the number of vegetative cells. Further han-
dling of the sample depends on the type of analysis 
to be performed [29-31].
The currently performed CDI diagnostic tests are 
screening tests that allow determination of the sus-
pected infection, including: detecting the bacterial 
strain, or both toxins (A and B), or one of them, di-
rectly in a stool sample. The available CDI diagnostic 
tests are based on: toxigenic culture (TC), molecular 
tests (nucleic acid amplification test – NAAT), testing 
for glutamate dehydrogenase (an enzyme produced 
in large quantities by all toxin-releasing strains, as 
well as by strains that do not release toxins, making 
it an excellent diagnostic marker), cytotoxicity tests 
(CCNA), and enzyme immunoassays towards toxins A 
and B [3, 27].
EpIdEmIology
The spread of CDI is a  serious epidemiological 
problem in a hospital setting. This is related to the 
emergence of new strains that are resistant to mul-
tiple antibiotics [3, 32, 33]. The B1/NAP1/027 strain is 
particularly virulent, causing infections with a much 
more severe clinical course and higher mortality 
than prior strains. It is characterised by a high de-
gree of resistance to antibiotics, increased ability 
to form spores, higher production of toxins A and 
B (16 and 23 times more than other strains, respec-
tively), as well as production of an additional binary 
toxin [3, 34]. In the conducted studies, an increase in 
the incidence of C. difficile infections caused by the 
NAP1 strain was found in several hospitals; for ex-
ample, in 2005 there was an increase from 10 cases 
to 33 cases per 100,000 patients [3, 32]. A study con-
ducted in 2014 in 20 EU countries found an average 
of seven cases of CDI per 10,000 patient days of hos-
pitalreation [3, 35], while in 2016, according to the 
ECDC, there were already 7.4 cases per 10,000 pa-
tient days [6, 36].
According to data collected by the Polish Na-
tional Institute of Public Health – National Institute 
of Hygiene (Narodowy Instytut Zdrowia Publicznego 
– Państwowy Zakład Higieny – NIZP-PZH), the inci-
dence of CDI is growing also in Poland – in 2016 there 
was an average of 22.7 cases per 100,000  inhabit-
ants, while in 2017 this rate was already at 30.4 cas-
es per 100,000 inhabitants [37]. As a  result of re-
search conducted in 2011-2013, covering 13 cities in 
Poland, it was found that the most common cause 
of CDI was strain B1/NAP1/027, which accounted for 
62% compared to other strains [38]. However, the 
same type of strain in 2017 caused 80% of cases in 
Silesia [39].
trEatmEnt
According to guidelines issued by the Infectious 
Diseases Society of America (IDSA) and Society for 
Healthcare Epidemiology of America (SHEA), CDI 
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should be treated with orally administered vanco-
mycin (dose 125 mg four times per day) or fidaxo-
micin (dose 200 mg twice a day) for 10 days [27]. If 
there is no improvement within 48 hours, the dose 
of vancomycin can be increased up to 500 mg four 
times per day [40]. In cases of mild infections or if 
vancomycin or fidaxomicin is not available, metroni-
dazole (500 mg three times daily for 10 days) may be 
administered [4, 41]. Due to its cumulative and neu-
rotoxic effects metronidazole treatment should not 
be repeated or prolonged. In cases of fulminant CDI 
with hypotension or shock, obstruction, or mega-
colon, additional rectal administration of vancomy-
cin (500 mg every six hours) should be considered, 
and, additionally, metronidazole treatment should 
be also introduced  [27]. In patients with recurrent 
infections, intestinal faecal microbiota transplan-
tation (FMT) is recommended. Treatment involves 
administering a human stool from a healthy donor 
to the intestine of a sick patient to restore normal 
intestinal microflora. The most common methods of 
stool administration are retention enema, colonos-
copy, and infusion through a nasogastric tube. Fae-
cal transplant is a low-cost, low-risk, highly effective 
treatment [42]. 
prEvEntIon
A basic and, at the same time, the most difficult 
(especially in ICU environments) means of reducing 
the risk of C. difficile infections is to reduce the num-
ber of antibiotics used.
The rapid spread of C. difficile infections is highly 
dangerous for patients in ICUs, causing deteriora-
tion of health through severe complications and even 
death.
Due to frequent infectious complications, and 
the resulting treatment with broad-spectrum anti-
biotics, these patients are particularly vulnerable to 
the spread of drug-resistant microorganisms. Nurses 
who have direct contact with the patient, perform 
many activities with the patient (e.g. body toilet), or 
take part in many procedures and tests (e.g. in the 
pharmacotherapy or FMT) play a  significant role in 
preventing the transmission of infections. Table 1 is 
a  summary of key aspects of CDI in ICU in nursing 
practice. In order to prevent C. difficile infections, it is 
very important to take appropriate measures, which 
include: 
• hand hygiene and use of personal protective 
equipment,
• patient isolation,
• maintaining cleanliness with disinfection,
• infected patient care,
• education of visitors,
• surveillance.
Hand HygIEnE and pErsonal 
protEctIvE EquIpmEnt
According to the World Health Organisation (WHO), 
the key element in prevention of hospital infections is 
proper hand hygiene and the application of the “five 
moments for hand hygiene” rule: before touching a pa-
Table 1. Summary of key aspects of C. difficile infection in ICUs 
in nursing practice
Policy aspect Nursing intervention
Diagnosis and 
care
• Assess the frequency of defecation 
and measure stool amounts and 
characteristics
• Assess the history of antibiotic use
• Monitor vital signs – temperature, blood 
pressure, heart rate, urine output, and 
mental status
• Assess signs and symptoms (severe 
abdominal pain, fever, nausea, vomiting, 
hypovolaemia)
• Obtain stool specimens according to the 
procedure
• Promote comfort and maintain skin 
integrity – use of a closed system for 
controlled stool collection, proper skin 
care, use of protective and barrier 
creams and lotions
• Prevention of patients’ emotional stress 
associated with being in isolation
Isolation 
precautions
• Single-occupancy rooms for patients 
with CDI
• Patients hospitalised in multi-bed 
rooms – recommended that  
a dedicated isolation space be separated 
within the patient’s room
• Use disposable equipment
• Hand hygiene – soap or chlorhexidine-
based sanitisers should be used
• Personal protective equipment: 
disposable gloves, gowns, disposable 
protective clothing
• Recommended chlorine-based 
preparations for disinfection of surfaces





• Traditional pharmacological treatment 
of CDI should be started only after 
testing for C. difficile is completed
• Pharmacological treatment according to 
guidelines (vancomycin or fidaxomicin 
or metronidazole)
• Patients should be monitored for 
vancomycin resistance
• FMT recommended after a third 
recurrence of the infection
• Prepare the FMT stool: 200-300 g stool 
from a healthy donor, mixed with 
physiological saline or water to make  
a liquid slurry, filtered and then instilled 
in the upper or lower part of the 
gastrointestinal tract
• Patients’ and relatives’ education and 
psychological support 
CDI – Clostridioides difficile infection, ICU – intensive care unit,  
FMT – faecal microbiota transplantation
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least 48 hours after diarrhoea is resolved and can be 
maintained until the patient is discharged, especially 
if there is an increased incidence rate in the unit [3]. 
It is also advised that transport of CDI patients is lim-
ited, although this is often impossible in the case of 
patients in critical condition requiring proper imaging 
diagnostics. If a patient is discharged to another ward 
or to another hospital, thorough information should 
be provided by medical staff at discharge about the 
suspicion or diagnosis of CDI and the need to imple-
ment appropriate procedures [45, 49].
maIntaInIng clEanlInEss  
wItH dIsInfEctIon
The spread of CDI is largely associated with the 
production of spores, which are resistant to external 
factors like drying, and low or high temperatures. 
Therefore, it is strongly recommended to use dispos-
able equipment. Multiple-use patient-care equipment 
(blood pressure meter, pulse oximeter) can be dedi-
cated for the patient infected with C. difficile – equip-
ment after use should be decontaminated, for exam-
ple, through sterilisation. Chlorine-based preparations 
are recommended for disinfection of surfaces. It is rec-
ommended that the patient’s room is cleaned and dis-
infected every day, as well as surfaces and equipment 
from the patient’s surroundings. Sporicidal agents 
should also be used for disinfection after patient dis-
charge. Dirty personal and bed linen should be closed 
in a separate bag at the place of isolation [3, 45, 49].
InfEctEd patIEnt carE
In the case of diarrhoea, barrier preparations 
should be used, which form a  protective layer and 
a screen between the skin and the liquid stool. In CDI 
spores are excreted in large quantities with faeces. 
Hence, proper care and maintenance of skin clean-
liness in patients in critical condition are very im-
portant. The search for optimal solutions for care in 
patients with diarrhoea in intensive care units con-
tinues worldwide. Standards of conduct are aimed at 
creating safety for both the patient and the staff. One 
of the methods of nursing patients with diarrhoea 
in ICUs is the use of a closed system for controlled 
stool collection. The system consists of a soft, silicone 
sleeve, about 1.5 m long, equipped with a silicone, low-
pressure balloon at one end, and at the other – with 
a flange for connecting to a collecting bag. The bal-
loon is introduced through the anal sphincter so that 
it is in the rectal bubble. The system is easy to use. Its 
use reduces the risk of skin damage through effective 
control and drainage of liquid faeces. It protects the 
skin against the harmful effects of faecal enzymes 
that damage the epidermis, increasing the risk of 
infections and of appearance of wounds around the 
tient, before clean/aseptic procedures, after body fluid 
exposure/risk, after touching a patient, and after touch-
ing the patient’s surroundings [43]. It is estimated that 
the most common cause (60-90%) of infections is the 
transmission of pathogens present on the hands of 
medical personnel [44].
According to current Centers for Disease Control 
and Prevention (CDC) recommendations, in the case of 
a patient with CDI, hand hygiene should be performed 
routinely and in endemic situations before and after 
contact with the patient and after removing gloves.
It is strongly recommended to perform hand hy-
giene, routinely and in endemic situations, through 
washing with soap under running water or disinfect-
ing with an alcohol-based hand rub [3].
However, if there is an epidemiological outbreak 
or a high incidence rate of CDI, or in the case of direct 
contact with faecal flora, soap or chlorhexidine-based 
sanitisers should be used for hand hygiene [45]. Soap 
and/or chlorhexidine preparations remove spores 
more effectively compared to alcohol-based hand sa-
nitisers. Additional barriers such as disposable gloves 
and gowns should also be used to reduce the spread 
of infection. Personal protective equipment should be 
used when entering the patient’s room and during 
any activities performed with the patient and in their 
environment [3].
patIEnt IsolatIon
Contact isolation is aimed at preventing the 
spread of infections through direct contact (between 
staff and the patient, between patients, and between 
the environment and patients) and indirect contact 
(e.g. through shared equipment) [46].
In cases of suspicion or diagnosis of CDI, contact 
isolation of the patient (room with airlock) should be 
implemented. If the use of a  single-patient room is 
not possible, especially in the ICU, where patients are 
often hospitalised in multi-bed rooms, it is recom-
mended that a dedicated isolation space within the 
patients’ room is separated [47]. In the case of isola-
tion in multiple-patient rooms, it is strongly recom-
mended by the IDSA and SHEA to separate patients 
with C. difficile from patients colonised simultane-
ously with various multiresistant microorganisms, e.g. 
MRSA (Staphylococcus aureus) and VRE (Enterococcus 
spp.) [27, 28]. Unfortunately, according to the reports 
of the Polish Supreme Audit Office (Najwyższa Izba 
Kontroli, NIK) and studies performed in many cen-
tres in Poland, it appears that over 40% of all hospi-
tal infections, either recognised at admission or due 
to treatment complications, are recorded in patients 
hospitalised in ICUs [48, 49]. This is why presumptive 
isolation of patients in whom C. difficile is suspected 
or while awaiting diagnostic test results is so impor-
tant. Contact isolation should be continued for at 
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anus. Using a closed system for controlled stool col-
lection also reduces the risk of cross-contamination, 
saves the work time of medical personnel, and limits 
the amount of used dressings. The system also allows 
accurate calculation of the amount of stool donated, 
which is important in critically ill patients, in whom 
diarrhoea may cause dehydration. Therefore, it is very 
important for these patients to keep a fluid balance 
card describing the amount of fluid intake and excre-
tion. Skin care is another important element of care 
for patients with C. difficile. The skin performs one of 
the most important functions – a protective function. 
The possibility of skin damage associated with urinary 
and/or faecal incontinence (incontinence-associated 
dermatitis – IAD), in this case caused by C.  difficile 
diarrhoea, requires appropriate care. Patient cleaning 
products require one-time use, wet towels with a bal-
anced pH and containing dimethicone, having skin 
protective properties. For the prevention of IAD, it is 
recommended to use protective and barrier creams 
and lotions. These preparations form a  transparent 
protective layer, which reduces the risk of dermatitis 
associated with the action of liquid stool [50-52].
EducatIon of vIsItors
Another important element in preventing the 
spread of C. difficile is educating the families and per-
sons visiting a given patient. The very fact of a close 
person being hospitalised in an intensive care unit is 
very stressful, so it is worth explaining the rules of con-
duct to the family in a simple and approachable way. 
Most importantly, hand hygiene – showing the proper 
technique of hand washing using soap and water, 
putting on gloves and disposable protective clothing. 
The family should be shown how and where medical 
waste is segregated. It should be stressed that visitors 
should not sit on the bed of the patient, nor should 
they put their clothes or objects of everyday use (bags, 
phones, etc.) on the patient’s linen or on the floor. It is 
not advisable that the patient be visited by children or 
older people when infected [53, 54].
survEIllancE
Currently, one of the most important health policy 
goals is to prevent the increase of microorganism 
drug resistance by applying relevant antibiotic policy 
and monitoring and recording infections. The task of 
a  Hospital Infections Control Team (Zespół Kontroli 
Zakażeń Szpitalnych – ZKZSZ) is to manage infection 
control. Active surveillance includes proper health-
care-associated surveillance with infections preven-
tion and control, monitoring procedures, conducting 
internal training on proper hand hygiene and patient 
isolation, as well as controlling use of antibiotics [45, 
49, 55, 56].
In intensive care units, discontinuation of antibi-
otics is difficult, if not impossible, due to the presence 
of various infections in one patient at the same time. 
In addition, studies found that about 10-30% of hos-
pitalised patients, as well as a significant proportion 
of medical personnel, had asymptomatic C. difficile 
[3, 57], which may contribute to the spread of infec-
tion in the hospital [58, 59]. All patients hospitalised 
in the ICUs with symptoms of: “acute abdomen” for 
no known reason, diarrhoea with increased leukocy-
tosis, or after antibiotic therapy or after treatment 
with proton pump inhibitors, should be screened for 
infection [45].
It is also very important to control the implemen-
tation of guidelines and recommendations for treat-
ment and procedures. It is equally important to con-
duct continuous internal training, both among young, 
inexperienced nursing staff who still have insufficient 
knowledge and are prone to make mistakes, as well 
as among senior nurses who should continuously up-
date their knowledge [60].
conclusIons
Due to an increase in CDI incidence caused by CDI 
in ICUs, it is very important to quickly diagnose pa-
tients and implement appropriate treatment as well 
as proper monitoring and registration of infections.
Nurses play a key role in recognising the symptoms 
of infection and preventing the spread of C. difficile. 
Following procedures, meticulous hand hygiene, com-
pliance with patient isolation protocols, and proper 
education of staff and visitors are the foundations for 
effective prevention of C. difficile transmission.
Disclosure 
The authors declare no conflict of interest. 
References
1. Bartnik W, Szczepanek M, Rymer W. Zakażenie Clostridiodes 
(Clostridium) difficile i rzekomobłoniaste zapalenie jelit. 
In: Gajewski P, Szczeklik A. Interna Szczeklika 2018. Medycyna 
Praktyczna 2018; 1072-1075.
2. Guh AY, Kutty PK. Clostridioides difficile Infection. Ann Intern 
Med 2018; 169: 49-64.
3. Martirosian G, Hryniewicz W, Ozorowski T, et al. Zakażenia 
Clostridioides (Clostridium) difficile: epidemiologia, diagno-
styka, terapia, profilaktyka. Narodowy Instytut Leków, 2018. 
www.antybiotyki.edu.pl.
4. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl 
J Med 2015; 373: 287-288.
5. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, et al. Risk 
factors for Clostridium difficile toxin-positive diarrhea: 
a population-based prospective case-control study. Eur J Clin 
Microbiol Infect Dis 2012; 31: 2601-2610.
6. Huang H, Wu S, Chen R, et al. Risk factors of Clostridium 
difficile infections among patients in a university hospital 
in Shanghai, China. Anaerobe 2014; 30: 65-69.
17Nursing Problems 1/2020 
Clostridioides diffiCile infection in intensive care units in nursing practice
7. Lee-Tsai YL, Luna-Santiago R, Demichelis-Gómez R, et al. 
Determining the risk factors associated with the develop-
ment of Clostridium difficile infection in patients with 
hematological diseases. Blood Res 2019; 54: 120-124.
8. Barletta JF, El-Ibiary SY, Davis LE, et al. Proton Pump Inhibi-
tors and the Risk for Hospital-Acquired Clostridium difficile 
Infection. Mayo Clin Proc 2013; 88: 1085-1090.
9. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen 
factors for Clostridium difficile infection and colonization. 
N Engl J Med 2011; 365: 1693-1703.
10. Tirath A, Tadros S, Coffin SL, et al. Clostridium difficile infec-
tion in dialysis patients. J Investig Med 2017; 65: 353-357.
11. Chaughtai S, Gandhi B, Chaughtai Z, et al. Clostridium dif-
ficile peritonitis: an emerging infection in peritoneal dialysis 
patients. Case Rep Med 2018; 2018: 3537283.
12. Gualtero SM, Abril LA, Camelo N, et al. Characteristics of 
Clostridium difficile infection in a high complexity hospital 
and report of the circulation of the NAP1/027 hypervirulent 
strain in Colombia. Biomedica 2017; 37: 466-472.
13. Guery B, Galperine T, Barbut F. Clostridioides difficile: diag-
nosis and treatments. BMJ 2019; 366: I4609.
14. Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-
associated risk factors for Clostridium difficile infection. Clin 
Infect Dis 2008; 46: 19-31.
15. Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of 
increased risk for Clostridium difficile infection after exposure 
to antibiotics. J Antimicrob Chemother 2012; 67: 742-748.
16. King RN, Lager SL. Incidence of Clostridium difficile infections 
in patients receiving antimicrobial and acid-suppression 
therapy. Pharmacotherapy 2011; 31: 642-648.
17. Gordon D, Young LR, Reddy S, et al. Incidence of Clostridium 
difficile infection in patients receiving high-risk antibiotics 
with or without a proton pump inhibitor. J Hosp Infect 2016; 
92: 173-177.
18. Barra-Carrasco J, Paredes-Sabja D. Clostridium difficile 
spores: a major threat to the hospital environment. Future 
Microbiol 2014; 9: 475-486.
19. Gómez S, Chaves F, Orellana MA. Clinical, epidemiological and 
microbiological characteristics of relapse and re-infection in 
Clostridium difficile infection. Anaerobe 2017; 48: 147-151.
20. Chilton CH, Pickering DS, Freeman J. Microbiologic factors 
affecting Clostridium difficile recurrence. Clin Microbiol Infect 
2018; 24: 476-482.
21. Czepiel J, Kędzierska J, Biesiada G, et al. Epidemiology of Clos-
tridium difficile infection: results of a hospital-based study 
in Krakow, Poland. Epidemiol Infect 2015; 143: 3235-3243.
22. Ziółkowski G, Pawłowska I, Krawczyk L, et al. Antibiotic 
consumption versus the prevalence of multidrug-resistant 
Acinetobacter baumannii and Clostridium difficile infec-
tions at an ICU from 2014–2015. J Infect Public Health 2018; 
11: 626-630.
23. Jasiak NM, Alaniz C, Rao K, et al. Recurrent Clostridium dif-
ficile infection in intensive care unit patients. Am J Infect 
Control 2016; 44: 36-40.
24. Dziennik Urzędowy Unii Europejskiej. 2018/945 z dnia 
22 czerwca 2018 r. L 170/1.
25. Caroff DA, Edelstein PH, Hamilton K, et al. The Bristol stool 
scale and its relationship to Clostridium difficile infection. 
J Clin Microbiol 2014; 52: 3437-3439.
26. Zimmaro Bliss D, Dhamani KA, Savik K, et al. Tool to classify 
stool consistency: content validity and use by persons of 
diverse cultures. Nurs Health Sci 2003; 5: 115-121.
27. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice 
guidelines for Clostridium difficile infection in adults and 
children: 2017 Update by the Infectious Diseases Society of 
America (IDSA) and Society for Healthcare Epidemiology of 
America (SHEA). Clin Infect Dis 2018; 66: 1-48.
28. Tschudin-Sutter S, Kuijper EJ, Durovic A, et al. Guidance docu-
ment for prevention of Clostridium difficile infection in acute 
healthcare settings. Clin Microbiol Infect 2018; 24: 1051-1054.
29. Gateau C, Couturier J, Coia J, et al. How to: diagnose infection 
caused by Clostridium difficile. Clin Microbiol Infect 2018; 
24: 463-468.
30. Barbut F, Surgers L, Eckert C, et al. Does a rapid diagnosis of 
Clostridium difficile infection impact on quality of patient 
management? Clin Microbiol Infect 2014; 20: 136-144.
31. Freeman J, Wilcox MH. The effects of storage conditions on 
viability of Clostridium difficile vegetative cells and spores and 
toxin activity in human faeces. J Clin Pathol 2003; 56: 126-128.
32. Kuijper EJ, Barbut F, Brazier JS, et al. Update of Clostridium 
difficile infection due to PCR ribotype 027 in Europe, 2008. 
Euro Surveill 2008; 13. 
33. Nyč O, Pituch H, Matějková J, et al. Clostridium difficile PCR 
ribotype 176 in the Czech Republic and Poland. Lancet 2011; 
377: 1407.
34. Pituch H, Bakker D, Kuijper E, et al. First isolation of Clos-
tridium difficile PCR-ribotype 027/toxinotype III in Poland. 
Pol J Microbiol 2008; 57: 267-268.
35. Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis 
of Clostridium difficile across Europe: the European, mul-
ticentre, prospective, biannual, point-prevalence study of 
Clostridium difficile infection in hospitalised patients with 
diarrhoea (EUCLID). Lancet Infect Dis 2014; 14: 1208-1219.
36. ECDC: European surveillance of Clostridium difficile infections. 
Surveillance protocol version 2.3. Stockholm: ECDC 2017.
37. http://wwwold.pzh.gov.pl/oldpage/epimeld/2017/Ch_2017_
wstepne_dane.pdf
38. Pituch H, Obuch-Woszczatyński P, Lachowicz D, et al. Hospi-
tal-based Clostridium difficile infection surveillance reveals 
high proportions of PCR ribotypes 027 and 176 in different 
areas of Poland, 2011 to 2013. Euro Surveill 2015; 20.
39. Aptekorz M, Szczegielniak A, Wiechuła B, et al. Occurrence 
of Clostridium difficile ribotype 027 in hospitals of Silesia, 
Poland. Anaerobe 2017; 45: 106-113.
40. Baines SD, Chilton CH, Crowther GS, et al. Evaluation of 
antimicrobial activity of ceftaroline against Clostridium dif-
ficile and propensity to induce C. difficile infection in an in 
vitro human gut model. J Antimicrob Chemother 2013; 68: 
1842-1849.
41. Ooijevaar RE, van Beurden YH, Terveer EM, et al. Update of 
treatment algorithms for Clostridium difficile infection. Clin 
Microbiol Infect 2018; 24: 452-462.
42. Boyle ML, Ruth-Sahd LA, ZhouZ. Fecal microbiota transplant 
to treat recurrent Clostridium difficile infections. Crit Care 
Nurse 2015; 35: 51-65.
43. WHO Guidelines on Hand Hygiene in Health Care: First 
Global Patient Safety Challenge Clean Care is Safer Care. 
World Health Organization 2009.
44. Fleischer M. Higiena rąk. Zakażenia Szpitalne 2014; 1: 11-13.
45. Hryniewicz W, Martirosian G, Ozorowski T. Zakażenia Clostri-
dium difficile. Diagnostyka, terapia, profilaktyka. Narodowy 
Instytut Leków, Warszawa 2011.
46. Siegel JD, Rhinehart E, Jackson M, et al. Management of 
multidrug-resistant organisms in health care settings, 2006. 
Am J Infect Control 2007; 35: 165-193.
47. Gaszyński W. Zakażenia szpitalne w Oddziale Intensywnej 
Terapii. In: Denys A (ed.). Zakażenia szpitalne w wybranych 
oddziałach: Część II. Wolters Kluwer 2013; 257-301.
18
Izabela Fajfer-Gryz, Ilona Nowak-Kózka, Joanna Rudek
Nursing Problems 1/2020 
48. https://www.nik.gov.pl/aktualnosci/zakazenia-w-szpitalach-
powaznym-problemem.html.
49. Miętkiewicz S, Nowaczyk B. Profilaktyka i kontrola zakażeń 
na oddziałach anestezjologii i intensywnej terapii. In: Dyk D, 
Gutysz-Wojnicka A. Pielęgniarstwo anestezjologiczne i inten-
sywnej terapii. PZWL, Warszawa 2018; 256-264.
50. Rudek J. Zamknięty system do kontrolowanej zbiórki stolca 
jako alternatywna metoda pielęgnacji pacjenta z biegunką 
w oddziale intensywnej terapii. Forum Zakażeń 2014; 5: 7-15.
51. Van den Bussche K, Kottner J, Beele H, et al. Core outcome 
domains in incontinence-associated dermatitis research. 
J Adv Nurs 2018; 74: 1605-1617.
52. Beeckman D, Van Damme N, Schoonhoven I, et al. Interven-
tions for preventing and treating incontinence-associated 
dermatitis in adults. Cochrane Database Syst Rev 2016; 11.
53. Alhmidi H, Cadnum JL, Piedrahita CT, et al. Evaluation of an 
automated ultraviolet-C light disinfection device and patient 
hand hygiene for reduction of pathogen transfer from inter-
active touchscreen computer kiosks. Am J Infect Control 
2018; 46: 464-467.
54. Fletcher KR, Cinalli M. Identification, optimal management, 
and infection control measures for Clostridium difficile-
associated disease in long-term care. Geriatr Nurs 2007; 
28: 171-181.
55. Wieder-Huszla S. Monitorowanie zakażeń szpitalnych na 
oddziale intensywnej terapii medycznej. Ann Acad Med 
Stetin 2010; 56: 20-29.
56. Sierocka A, Cianciara M. Monitorowanie zakażeń szpitalnych. 
Prob Hig Epidemiol 2010; 91: 323-328.
57. Szczęsny A, Martirosian G. Epidemiologia zakażeń Clostri-
dium difficile. Przegl Epidemiol 2002; 56: 49-56.
58. Caroff DA, Yokoe DS, Klompas M. Evolving insights into the 
epidemiology and control of Clostridium difficile in hospitals. 
Clin Infect Dis 2017; 65: 1232-1238.
59. Durovic A, Widmer AF, Tschudin-Sutter S. New insights into 
transmissions of Clostridium difficile infection – narrative 
review. Clin Microbiol Infect 2018; 24: 483-492.
60. Łoś I, Dziewulska J. Wiedza personelu pielęgniarskiego na 
temat Clostridium difficile. Aspekty Zdrowia i Choroby 2018; 
3: 109-132.
